RYR2 mutation in non-small cell lung cancer prolongs survival via down-regulation of DKK1 and up-regulation of GS1-115G20.1: A weighted gene Co-expression network analysis and risk prognostic models
机构：[1]Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China[2]Kunming Medical University, Kunming, Yunnan, China[3]Department of Cardiovascular Surgery, The First People's Hospital of Yunnan Province, Kunming, China外科片心脏大血管外科云南省第一人民医院[4]Department of Cardiovascular Surgery, Affiliated Hospital of Kunming University of Science and Technology, Kunming, China[5]First Department of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China[6]Second Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
RYR2 mutation is clinically frequent in non-small cell lung cancer (NSCLC) with its function being elusive. We downloaded lung squamous cell carcinoma and lung adenocarcinoma samples from the TCGA database, split the samples into RYR2 mutant group (n = 337) and RYR2 wild group (n = 634), and established Kaplan-Meier curves. The results showed that RYR2 mutant group lived longer than the wild group (p = 0.027). Weighted gene co-expression network analysis (WGCNA) of differentially expressed genes (DEGs) yielded prognosis-related genes. Five mRNAs and 10 lncRNAs were selected to build survival prognostic models with other clinical features. The AUCs of 2 models are 0.622 and 0.565 for predicting survival at 3 years. Among these genes, the AUCs of DKK1 and GS1-115G20.1 expression levels were 0.607 and 0.560, respectively, which predicted the 3-year survival rate of NSCLC sufferers. GSEA identified an association of high DKK1 expression with TP53, MTOR, and VEGF expression. Several target miRNAs interacting with GS1-115G20.1 were observed to show the relationship with the phenotype, treatment, and survival of NSCLC. NSCLC patients with RYR2 mutation may obtain better prognosis by down-regulating DKK1 and up-regulating GS1-115G20.1.
基金：
the Open Project of The First People's Hospital of
Yunnan Province Clinical Medicine Center, Grant/
Award Number: 2021LCZXXF‐XZ03; the Applied
Basic Research Project of Yunnan provincial Science
and Technology Department and Kunming Medical
University, Grant/Award Numbers:
202001AY070001‐117, 202001AY070001‐130,
202001AY070001‐284
第一作者机构：[1]Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China[2]Kunming Medical University, Kunming, Yunnan, China[3]Department of Cardiovascular Surgery, The First People's Hospital of Yunnan Province, Kunming, China[4]Department of Cardiovascular Surgery, Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China[2]Kunming Medical University, Kunming, Yunnan, China[*1]Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China.
推荐引用方式(GB/T 7714)：
Ren Wenjun,Li Yongwu,Chen Xi,et al.RYR2 mutation in non-small cell lung cancer prolongs survival via down-regulation of DKK1 and up-regulation of GS1-115G20.1: A weighted gene Co-expression network analysis and risk prognostic models[J].IET SYSTEMS BIOLOGY.2022,16(2):43-58.doi:10.1049/syb2.12038.
APA：
Ren, Wenjun,Li, Yongwu,Chen, Xi,Hu, Sheng,Cheng, Wanli...&Wang, Ping.(2022).RYR2 mutation in non-small cell lung cancer prolongs survival via down-regulation of DKK1 and up-regulation of GS1-115G20.1: A weighted gene Co-expression network analysis and risk prognostic models.IET SYSTEMS BIOLOGY,16,(2)
MLA：
Ren, Wenjun,et al."RYR2 mutation in non-small cell lung cancer prolongs survival via down-regulation of DKK1 and up-regulation of GS1-115G20.1: A weighted gene Co-expression network analysis and risk prognostic models".IET SYSTEMS BIOLOGY 16..2(2022):43-58
